VN
Organon (2) Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Elyea (relugolix combo) | Heavy Menstrual Bleeding with Uterine Fibroids; Endometriosis Pain | Approved |
| Phexxi | Non-hormonal Contraceptive | Approved |
| Orilissa (elagolix) | Endometriosis Pain | Approved |
| Biosimilar Aflibercept | Ophthalmology (nAMD, DME) | Filed |
| Biosimilar Denosumab | Osteoporosis, Bone Metastasis | Phase 3 |
| Biosimilar Ranibizumab | Ophthalmology (nAMD, DME, RVO) | Phase 3 |
| Biosimilar Ustekinumab | Plaque Psoriasis, Psoriatic Arthritis, IBD | Phase 3 |
| Biosimilar Bevacizumab | Oncology | Phase 3 |
Leadership Team at Organon (2)
CC
Carrie Cox
Executive Board Chair
JM
Joseph Morrissey
Interim CEO
JC
Juan Camilo Arjona Ferreira
Head of R&D and Chief Medical Officer
MC
Mike Casia
Interim Head of U.S. Commercial & Government Affairs
JD
Juliana Drinane
Interim Head of Manufacturing and Supply
AF
Aaron Falcione
Chief Human Resources Officer
DK
Daniel Karp
Head of Corporate Development and Chief Strategy Officer
RS
Rachel Stahler
Chief Digital and Growth Officer
NV
Nico Van Hoecke
Head of International Commercial
MW
Matthew Walsh
Chief Financial Officer